FLT3 and acute myeloid leukemia: Several small molecule FLT3 inhibitors (FLT3is), including midostaurin and quizartinib, have been developed for treatment of FLT3-ITD AML, but their application as monotherapy has shown limited and transient clinical responses, with the majority of patients experiencing relapse and developing resistance shortly thereafter [7, 8].